Shares of Xoma (XOMA) are down $7.36 to $27.00 in premarket trading after the company’s partner Rezolute (RZLT) announced that ersodetug failed in a Phase 3 congenital hyperinsulinism study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA: